{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Metabolic Enzyme & Protease > AprotininCAS：9087-70-1
Molecular Formula：C284H432N84O79S7
Molecular Weight：6511.44
Storage：Powder:-20℃，1 year;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：White to off-white Solid
Qty：
Size：
| CAS | 9087-70-1 |
| Name | Aprotinin |
| Molecular Formula | C284H432N84O79S7 |
| Molecular Weight | 6511.44 |
| Solubility | Soluble in Water ≥20mg/mL |
| Purity | ≥98% |
| Appearance | White to off-white Solid |
| Storage | Powder:-20℃，1 year;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| EC | EINECS 232-994-9 |
| MDL | MFCD00130541 |
| SMILES | [RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA] |
| InChIKey | ZPNFWUPYTFPOJU-UHFFFAOYSA-N |
| InChI | InChI=1S/C284H432N84O79S7/c1-21-144(9)222-271(439)337-174(68-46-105-309-282(300)301)239(407)340-187(120-160-77-85-164(374)86-78-160)251(419)341-185(116-156-55-29-24-30-56-156)250(418)342-188(121-161-79-87-165(375)88-80-161)252(420)346-191(123-208(291)378)246(414)322-149(14)230(398)326-168(62-35-39-98-285)234(402)319-146(11)227(395)314-132-215(385)324-181(113-141(3)4)247(415)354-199-137-452-453-138-200-263(431)336-179(97-112-448-20)242(410)331-176(70-48-107-311-284(304)305)244(412)363-226(154(19)372)274(442)358-197(233(401)316-129-212(382)312-130-213(383)318-151(16)278(446)447)135-449-451-139-201(355-253(421)186(117-157-57-31-25-32-58-157)344-256(424)195(127-220(393)394)350-267(435)204-72-50-109-366(204)275(443)167(289)61-43-102-306-279(294)295)265(433)339-182(114-142(5)6)248(416)338-180(93-96-218(389)390)276(444)368-111-52-74-206(368)277(445)367-110-51-73-205(367)268(436)349-189(122-162-81-89-166(376)90-82-162)259(427)362-224(152(17)370)269(437)317-133-216(386)365-108-49-71-203(365)266(434)357-202(264(432)333-169(63-36-40-99-286)235(403)320-148(13)229(397)328-175(69-47-106-310-283(302)303)243(411)360-223(145(10)22-2)272(440)361-222)140-454-450-136-198(325-214(384)131-313-211(381)128-315-232(400)183(119-159-75-83-163(373)84-76-159)351-270(438)221(143(7)8)359-258(426)190(118-158-59-33-26-34-60-158)352-273(441)225(153(18)371)364-245(413)177(335-262(199)430)91-94-207(290)377)261(429)334-172(66-44-103-307-280(296)297)236(404)321-147(12)228(396)327-170(64-37-41-100-287)237(405)330-173(67-45-104-308-281(298)299)238(406)345-192(124-209(292)379)255(423)347-193(125-210(293)380)254(422)343-184(115-155-53-27-23-28-54-155)249(417)332-171(65-38-42-101-288)240(408)353-196(134-369)260(428)323-150(15)231(399)329-178(92-95-217(387)388)241(409)348-194(126-219(391)392)257(425)356-200/h23-34,53-60,75-90,141-154,167-206,221-226,369-376H,21-22,35-52,61-74,91-140,285-289H2,1-20H3,(H2,290,377)(H2,291,378)(H2,292,379)(H2,293,380)(H,312,382)(H,313,381)(H,314,395)(H,315,400)(H,316,401)(H,317,437)(H,318,383)(H,319,402)(H,320,403)(H,321,404)(H,322,414)(H,323,428)(H,324,385)(H,325,384)(H,326,398)(H,327,396)(H,328,397)(H,329,399)(H,330,405)(H,331,410)(H,332,417)(H,333,432)(H,334,429)(H,335,430)(H,336,431)(H,337,439)(H,338,416)(H,339,433)(H,340,407)(H,341,419)(H,342,418)(H,343,422)(H,344,424)(H,345,406)(H,346,420)(H,347,423)(H,348,409)(H,349,436)(H,350,435)(H,351,438)(H,352,441)(H,353,408)(H,354,415)(H,355,421)(H,356,425)(H,357,434)(H,358,442)(H,359,426)(H,360,411)(H,361,440)(H,362,427)(H,363,412)(H,364,413)(H,387,388)(H,389,390)(H,391,392)(H,393,394)(H,446,447)(H4,294,295,306)(H4,296,297,307)(H4,298,299,308)(H4,300,301,309)(H4,302,303,310)(H4,304,305,311) |
| PubChem CID | 22833874 |
| Target Point | Serine Protease |
| Passage | Metabolic Enzyme&Protease |
| Background | Aprotinin is a serine protease (BPTI) inhibitor. |
| Biological Activity | Aprotinin是丝氨酸蛋白酶 (BPTI) 抑制剂，对胰蛋白酶和胰凝乳蛋白酶胰凝乳蛋白酶的 Ki 值分别为0.06 pM和9 nM。[1-6] |
| Data Literature Source | [1]. Fritz H， et al. Biochemistry and applications of aprotinin， the kallikrein inhibitor from bovine organs. Arzneimittelforschung. 1983; 33 (4) :479-94. [2]. Levy JH， et al. Efficacy and safety of aprotinin in cardiac surgery. Orthopedics. 2004 Jun; 27 (6 Suppl) :s659-62. [3]. Venturini G， et al. Aprotinin， the first competitive protein inhibitor of NOS activity.Biochem Biophys Res Commun. 1998 Aug 10; 249 (1) :263-5 [4]. Sperzel M， et al. Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis， coagulation and thrombus formation. J Thromb Haemost. 2007 Oct; 5 (10) :2113-8. Epub 2007 Jul 31. [5]. Davis R， et al. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated withcardiac surgery. Drugs. 1995 Jun; 49 (6) :954-83. [6]. Sabbagh MJ， et al. Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I. J Cardiovasc Pharmacol. 2008 Oct; 52 (4) :355-62. |
| Unit | Bottle |
| Specification | 10mg 50mg 100mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
In ovo very early-in-life exposure to diesel exhaust induced cardiopulmonary toxicity in a hatchling chick model
Click to check >>Author：Jiang Q; Xu X; Zhang C; Luo J; Lv N; Shi L; Ji A;
IF：9.9880
Publish_to：Environ Pollut
PMID：32388309
Effect of cold and hot enzyme deactivation on the structural and functional properties of rice dreg protein hydrolysates
Click to check >>Author：XieH;HuangJ;WooMW;HuJ;XiongH;ZhaoQ
IF：7.2720
Publish_to：Food Chem
PMID：33302104
CoCl 2 increases the expression of hypoxic markers HIF-1α, VEGF and CXCR4 in breast cancer MCF-7 cells
Click to check >>Author：Li Q , Ma R , Zhang M .
IF：2.7850
Publish_to：Oncol Lett.
PMID：29391899
YKL-40 promotes proliferation and invasion of HTR-8/SVneo cells by activating akt/MMP9 signalling in placenta accreta spectrum disorders
Click to check >>Author：Weifang Liu, Runfang Wang, Suxin Liu, Xiaoqian Yin, Yan Huo, Ruiling Zhang, Jia Li
IF：1.2260
Publish_to：JOURNAL OF OBSTETRICS AND GYNAECOLOGY
PMID：37192383
Manual Download
